Anna Jirkovská

Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation

Eduard Jirkovský, Anna Jirkovská, Hana Bavlovič Piskáčková et al. · Circulation Heart Failure · 2021 · 53 citations · Full text

Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury

Hana Jansová, Miloslav Macháček, Qin Wang et al. · Free Radical Biology and Medicine · 2014 · 30 citations · Full text

Cardiomyocyte Oxidative Injury, Various Iron Chelators, Heart Failure +11

Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite

Jan Bureš, Anna Jirkovská, Vít Šesták et al. · Toxicology · 2017 · 27 citations

Significant Cardioprotective Effects, Biochemistry, Iron Chelating Metabolite +9

Proteomic investigation of embryonic rat heart-derived H9c2 cell line sheds new light on the molecular phenotype of the popular cell model

Juraj Lenčo, Olga Lenčová-Popelová, Marek Link et al. · Experimental Cell Research · 2015 · 25 citations

Embryonic Stem Cell, Cell Lineage, Human Cell +10

Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo

Anna Jirkovská, Jaroslav Roh, Olga Lenčová-Popelová et al. · Toxicology Research · 2015 · 22 citations · Full text

Heart Failure, Chemoprevention Strategy, Anthracycline Cardiotoxicity +16